Sarcopenia-defining parameters, but not sarcopenia, are associated with cognitive domains in middle-aged and older European men.
Cognition
Muscle mass
Muscle strength
Older adults
Physical performance
Sarcopenia
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
09
02
2023
received:
16
12
2022
accepted:
28
02
2023
medline:
5
6
2023
pubmed:
7
4
2023
entrez:
6
4
2023
Statut:
ppublish
Résumé
Previous research suggests that sarcopenia is associated with lower cognitive functioning. Evidence on the longitudinal relationship between cognition and sarcopenia, according to the revised criteria of the European Working Group on Sarcopenia in Older People (EWGSOP2), is scarce. This study aimed to investigate both cross-sectional and longitudinal associations between sarcopenia and its defining parameters (muscle strength, muscle mass and physical performance) and cognitive performance in middle-aged and older men. This was a secondary analysis of data from the European Male Ageing Study (EMAS), a multicentre cohort study of men aged 40-79 years, recruited from population registers in eight European centres. Cognitive functioning was assessed by using a battery of three neuropsychological tests, measuring fluid intelligence: Rey-Osterrieth Complex Figure (ROCF-Copy and ROCF-Recall), Camden Topographical Recognition Memory (CTRM) and Digit Symbol Substitution Test (DSST). Sarcopenia-defining parameters appendicular lean mass (aLM), gait speed (GS), chair stand test (CST) and handgrip strength (HGS) were measured. Sarcopenia was diagnosed according to the criteria of the EWGSOP2. All measurements were performed at baseline and after a follow-up of 4.3 years. Cross-sectional associations between cognition, sarcopenia-defining parameters and prevalent sarcopenia (EWGSOP2) were analysed. Longitudinally, the predictive value of baseline cognition on decline in sarcopenia-defining parameters, onset of new sarcopenia and vice versa was examined. Linear and logistic regression were used and adjusted for putative confounders. In the whole cohort (n = 3233), ROCF-Copy (β = 0.016; P < 0.05), ROCF-Recall (β = 0.010; P < 0.05), CTRM (β = 0.015; P < 0.05), DSST score (β = 0.032; P < 0.05) and fluid cognition (β = 0.036; P < 0.05) were significantly and independently associated with GS at baseline. In the Leuven + Manchester subcohorts (n = 456), ROCF-Copy (β = 1.008; P < 0.05), ROCF-Recall (β = 0.908; P < 0.05) and fluid cognition (β = 1.482; P < 0.05) were associated with HGS. ROCF-Copy (β = 0.394; P < 0.05), ROCF-Recall (β = 0.316; P < 0.05), DSST (β = 0.393; P < 0.05) and fluid cognition (β = 0.765; P < 0.05) were associated with aLM. The prevalence of sarcopenia in this population was 17.8%. No associations were detected between cognition and prevalent or incident sarcopenia. Longitudinal analysis showed that low ROCF-Copy score at baseline was associated with an increase in CST in men ≥70 years (β = -0.599; P < 0.05). In addition, a decrease in ROCF-Recall was associated with a decrease in GS, and a decrease in DSST was associated with an increase in CST (β = 0.155; P < 0.0001, β = -0.595; P < 0.001, respectively) in persons with the highest change in both cognition and muscle function. Sarcopenia was not associated with cognitive performance in this population, whereas several components of sarcopenia were associated with domain-specific cognitive performance. Longitudinally, baseline and change in subdomains of cognition predicted change in muscle function in specific subgroups.
Sections du résumé
BACKGROUND
Previous research suggests that sarcopenia is associated with lower cognitive functioning. Evidence on the longitudinal relationship between cognition and sarcopenia, according to the revised criteria of the European Working Group on Sarcopenia in Older People (EWGSOP2), is scarce. This study aimed to investigate both cross-sectional and longitudinal associations between sarcopenia and its defining parameters (muscle strength, muscle mass and physical performance) and cognitive performance in middle-aged and older men.
METHODS
This was a secondary analysis of data from the European Male Ageing Study (EMAS), a multicentre cohort study of men aged 40-79 years, recruited from population registers in eight European centres. Cognitive functioning was assessed by using a battery of three neuropsychological tests, measuring fluid intelligence: Rey-Osterrieth Complex Figure (ROCF-Copy and ROCF-Recall), Camden Topographical Recognition Memory (CTRM) and Digit Symbol Substitution Test (DSST). Sarcopenia-defining parameters appendicular lean mass (aLM), gait speed (GS), chair stand test (CST) and handgrip strength (HGS) were measured. Sarcopenia was diagnosed according to the criteria of the EWGSOP2. All measurements were performed at baseline and after a follow-up of 4.3 years. Cross-sectional associations between cognition, sarcopenia-defining parameters and prevalent sarcopenia (EWGSOP2) were analysed. Longitudinally, the predictive value of baseline cognition on decline in sarcopenia-defining parameters, onset of new sarcopenia and vice versa was examined. Linear and logistic regression were used and adjusted for putative confounders.
RESULTS
In the whole cohort (n = 3233), ROCF-Copy (β = 0.016; P < 0.05), ROCF-Recall (β = 0.010; P < 0.05), CTRM (β = 0.015; P < 0.05), DSST score (β = 0.032; P < 0.05) and fluid cognition (β = 0.036; P < 0.05) were significantly and independently associated with GS at baseline. In the Leuven + Manchester subcohorts (n = 456), ROCF-Copy (β = 1.008; P < 0.05), ROCF-Recall (β = 0.908; P < 0.05) and fluid cognition (β = 1.482; P < 0.05) were associated with HGS. ROCF-Copy (β = 0.394; P < 0.05), ROCF-Recall (β = 0.316; P < 0.05), DSST (β = 0.393; P < 0.05) and fluid cognition (β = 0.765; P < 0.05) were associated with aLM. The prevalence of sarcopenia in this population was 17.8%. No associations were detected between cognition and prevalent or incident sarcopenia. Longitudinal analysis showed that low ROCF-Copy score at baseline was associated with an increase in CST in men ≥70 years (β = -0.599; P < 0.05). In addition, a decrease in ROCF-Recall was associated with a decrease in GS, and a decrease in DSST was associated with an increase in CST (β = 0.155; P < 0.0001, β = -0.595; P < 0.001, respectively) in persons with the highest change in both cognition and muscle function.
CONCLUSIONS
Sarcopenia was not associated with cognitive performance in this population, whereas several components of sarcopenia were associated with domain-specific cognitive performance. Longitudinally, baseline and change in subdomains of cognition predicted change in muscle function in specific subgroups.
Identifiants
pubmed: 37021434
doi: 10.1002/jcsm.13229
pmc: PMC10235870
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1520-1532Informations de copyright
© 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Int J Geriatr Psychiatry. 2009 Nov;24(11):1257-66
pubmed: 19319924
Age Ageing. 2014 Nov;43(6):748-59
pubmed: 25241753
J Gerontol A Biol Sci Med Sci. 2020 Jun 18;75(7):1393-1402
pubmed: 31957799
Arch Intern Med. 2006 May 22;166(10):1115-20
pubmed: 16717174
Curr Opin Neurobiol. 2007 Dec;17(6):644-8
pubmed: 18337084
Arch Neurol. 1999 Mar;56(3):303-8
pubmed: 10190820
Clin Nutr. 2020 Sep;39(9):2695-2701
pubmed: 31917049
J Am Geriatr Soc. 1990 Oct;38(10):1105-12
pubmed: 2229864
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1848-1859
pubmed: 34535964
J Nutr Health Aging. 2011 Aug;15(8):706-10
pubmed: 21968869
Age Ageing. 2013 Mar;42(2):196-202
pubmed: 23221099
Age Ageing. 2012 Jul;41(4):506-12
pubmed: 22374646
Neuroepidemiology. 2008;31(3):167-73
pubmed: 18784415
Int J Androl. 2009 Feb;32(1):11-24
pubmed: 18328041
Nutr Clin Pract. 2016 Feb;31(1):40-8
pubmed: 26703961
Age Ageing. 2011 Jul;40(4):423-9
pubmed: 21624928
BMC Geriatr. 2021 May 6;21(1):292
pubmed: 33957882
Sci Rep. 2020 Jun 25;10(1):10367
pubmed: 32587294
J Clin Epidemiol. 1993 Feb;46(2):153-62
pubmed: 8437031
Psychosom Med. 2009 Jan;71(1):38-48
pubmed: 19124616
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Eur J Endocrinol. 2010 Jun;162(6):1155-64
pubmed: 20231367
Epidemiol Rev. 2013;35:33-50
pubmed: 23349427
J Am Geriatr Soc. 2021 Jul;69(7):1826-1835
pubmed: 33954985
J Cachexia Sarcopenia Muscle. 2013 Sep;4(3):225-9
pubmed: 23888380
Clin Interv Aging. 2018 Jun 06;13:1111-1119
pubmed: 29922049
Eur J Radiol. 1995 Jul;20(2):83-92
pubmed: 7588873
J Gerontol B Psychol Sci Soc Sci. 2016 Sep;71(5):841-8
pubmed: 25787083
J Am Geriatr Soc. 2002 Nov;50(11):1796-801
pubmed: 12410897
Arch Neurol. 2004 May;61(5):661-6
pubmed: 15148141
J Cachexia Sarcopenia Muscle. 2023 Jun;14(3):1520-1532
pubmed: 37021434
J Appl Physiol (1985). 1999 Sep;87(3):1163-71
pubmed: 10484591
Iran J Public Health. 2018 Mar;47(3):327-334
pubmed: 29845019
J Alzheimers Dis. 2019;71(s1):S65-S73
pubmed: 30814353
J Gerontol A Biol Sci Med Sci. 2010 Mar;65(3):300-6
pubmed: 19789197
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
BMC Geriatr. 2015 Dec 21;15:172
pubmed: 26692280